| Literature DB >> 35869364 |
Monica Kopec1, Naa Kwarley Quartey1, Michelle Snow1, Andrew Stechkevich1, Meredith Elana Giuliani1,2,3, Janet Papadakos4,5,6.
Abstract
Health information exchange between provider and patient, along with patient participation in their care (self-management), can lead to improved health outcomes. A step towards achieving better outcomes is the systematic provision of education materials to patients and caregivers throughout the cancer trajectory. An audit of patient education (PE) materials was conducted at a cancer center to identify content gaps and determine areas for future development. The PE audit was conducted in all outpatient clinics (13) and clinic-specific PE materials were identified, reviewed, and categorized by cancer type and under the following topics: About Cancer/Disease, Medical Tests and Imaging, Treatment, Symptom Management, Rehabilitation/Survivorship, General Wellbeing, Medical Device Care, Practical and Other. Four hundred forty-seven PE materials were included in the audit. Totals for each topic were summed and analyzed for education development opportunities. Results varied based on clinic and cancer type. Majority of the materials were found in the following clinics: Hematology (75), Genitourinary (74), and Gastrointestinal (57). The most common information topics were treatment (277), about cancer/disease (134), and symptom management (120). When broken down by cancer type, it was clear that while the collection of PE materials is well established for some diagnoses (e.g., 28 prostate cancer materials), there is a significant dearth in materials for others (e.g., 0 penile cancer materials). Audit results will be used to identify opportunities for future education material development. Determining cancer-specific information gaps is important in achieving equal information access for patients and caregivers, regardless of cancer diagnosis.Entities:
Keywords: Audit; Cancer; Cancer center; Cancer patient; Cancer trajectory; Information access; Information exchange; Information gaps; Patient education; Patient education material
Year: 2022 PMID: 35869364 PMCID: PMC9307263 DOI: 10.1007/s13187-022-02202-7
Source DB: PubMed Journal: J Cancer Educ ISSN: 0885-8195 Impact factor: 1.771
Categorization criteria for each content category
| Patient education content category | Categorization criteria |
|---|---|
| About Cancer/Disease | • Describes cancer and non-cancer-related illnesses |
| Medical Tests and Imaging | • Describes medical tests/procedures • Describes imaging tests/procedures |
| Treatment | • Describes any cancer treatments • Describes any non-cancer treatments |
| Symptom Management | • Managing side effects throughout the cancer journey (before, during, and after treatment) |
| Rehabilitation/Survivorship | • Life after cancer • Physiotherapy and exercise |
| General Wellbeing | • Psychological, social, spiritual, and emotional wellbeing support • Links to support materials not included—material must discuss support information directly |
| Medical Device Care | • Disassembling and reassembling devices • Cleaning devices |
| Practical | • Diet and exercise • Directions and accessibility • Patient logs/notebook entries • Managing everyday life before, during, and after treatments • Personal care • Prosthesis, hair accessories, personal products • Disease prevention |
| Other | • Materials containing links to other resources such as Web sites or videos • Materials about physicians at the cancer center |
Each of the 9 PE content categories with corresponding criteria used by the research assistant for categorization
Results table for outpatient clinics and cancer types that are treated within each clinic
| Clinic | Material count | About Cancer/Disease | Medical Tests and Imaging | Treatment | Symptom Management | Rehabilitation/Survivorship | General Wellbeing | Medical Device Care | Practical | Other |
|---|---|---|---|---|---|---|---|---|---|---|
| Brain metastases | ||||||||||
| Total | 18 | 8 | 2 | 13 | 12 | 1 | 3 | 0 | 2 | 0 |
| Breast | ||||||||||
| Ductal carcinoma in situ (DCIS) | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Invasive breast cancer (no metastasis) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Invasive breast cancer (metastasis) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| ASCT (general breast) | 50 | 12 | 11 | 28 | 10 | 12 | 13 | 2 | 8 | 0 |
| Total | 52 | 14 | 12 | 30 | 11 | 13 | 14 | 2 | 8 | 0 |
| Endocrine | ||||||||||
| Adrenal | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Parathyroid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pituitary | 2 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Thyroid | 10 | 2 | 6 | 5 | 1 | 1 | 2 | 0 | 1 | 0 |
| ASCT (general endocrine) | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 2 | 7 | 8 | 3 | 1 | 2 | 0 | 1 | 0 |
| Gastrointestinal | ||||||||||
| Ampullary | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Anal | 4 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 0 |
| Appendix | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Carcinoid | 4 | 4 | 1 | 3 | 2 | 1 | 2 | 0 | 4 | 0 |
| Colorectal | 13 | 2 | 1 | 5 | 0 | 1 | 2 | 0 | 3 | 3 |
| Esophageal | 4 | 1 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 0 |
| Gall bladder | 6 | 2 | 0 | 6 | 1 | 0 | 2 | 1 | 0 | 0 |
| Liver | 3 | 1 | 1 | 3 | 0 | 1 | 1 | 0 | 0 | 0 |
| Pancreatic | 7 | 3 | 2 | 6 | 2 | 1 | 1 | 0 | 2 | 0 |
| Stomach | 5 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 1 |
| ASCT (general gastrointestinal) | 10 | 0 | 0 | 7 | 1 | 0 | 0 | 3 | 3 | 0 |
| Total | 57 | 15 | 7 | 37 | 9 | 6 | 11 | 5 | 12 | 4 |
| Genitourinary | ||||||||||
| Bladder | 16 | 1 | 2 | 9 | 1 | 0 | 1 | 6 | 3 | 0 |
| Kidney | 7 | 3 | 2 | 5 | 0 | 0 | 1 | 1 | 2 | 0 |
| Penile | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Prostate | 28 | 7 | 7 | 22 | 7 | 1 | 6 | 1 | 11 | 0 |
| Testicular | 12 | 3 | 2 | 2 | 0 | 2 | 3 | 0 | 3 | 6 |
| ASCT (general genitourinary) | 11 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 2 | 6 |
| Total | 74 | 14 | 13 | 41 | 9 | 3 | 11 | 8 | 21 | 12 |
| Gynecology | ||||||||||
| Cervical | 5 | 3 | 4 | 1 | 1 | 1 | 1 | 0 | 1 | 0 |
| Uterine | 7 | 1 | 1 | 6 | 1 | 1 | 1 | 0 | 0 | 0 |
| Vulvar | 2 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Vaginal | 3 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 |
| Ovarian | 7 | 4 | 1 | 3 | 1 | 3 | 5 | 0 | 3 | 0 |
| Gestational trophoblastic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ASCT (general gynecology) | 26 | 2 | 2 | 16 | 16 | 0 | 2 | 0 | 8 | 0 |
| Total | 50 | 11 | 9 | 29 | 21 | 5 | 9 | 0 | 13 | 0 |
| Head and neck | ||||||||||
| Esophageal/tracheal | 5 | 1 | 1 | 3 | 1 | 1 | 1 | 3 | 0 | 0 |
| Laryngeal | 3 | 2 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 0 |
| Oropharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypopharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oral | 9 | 6 | 1 | 5 | 2 | 1 | 1 | 0 | 4 | 0 |
| Thyroid | 7 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 2 | 0 |
| ASCT (general head and neck) | 14 | 1 | 0 | 6 | 5 | 2 | 2 | 0 | 6 | 0 |
| Total | 38 | 10 | 8 | 17 | 8 | 5 | 5 | 4 | 13 | 0 |
| Hematology | ||||||||||
| Leukemia | 14 | 10 | 9 | 11 | 1 | 1 | 5 | 0 | 3 | 0 |
| Lymphoma | 8 | 6 | 4 | 6 | 1 | 2 | 3 | 0 | 4 | 0 |
| Multiple myeloma | 21 | 16 | 10 | 20 | 8 | 1 | 6 | 0 | 2 | 0 |
| ASCT (general hematology) | 32 | 6 | 4 | 22 | 11 | 1 | 7 | 0 | 13 | 0 |
| Total | 75 | 38 | 27 | 59 | 21 | 5 | 21 | 0 | 22 | 0 |
| Lung | ||||||||||
| Non-small cell | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Small cell | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Thymoma | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Mesothelioma | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| ASCT (general lung) | 26 | 9 | 8 | 16 | 10 | 3 | 3 | 4 | 2 | 1 |
| Total | 29 | 10 | 9 | 18 | 11 | 4 | 3 | 4 | 2 | 2 |
| Ocular | ||||||||||
| Total | 5 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 2 | 0 |
| Primary brain cancer | ||||||||||
| Glioblastoma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Meningioma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pituitary | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ASCT (general primary brain cancer) | 21 | 3 | 7 | 12 | 9 | 2 | 5 | 0 | 7 | 0 |
| Total | 21 | 3 | 7 | 12 | 9 | 2 | 5 | 0 | 7 | 0 |
| Sarcoma | ||||||||||
| Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Skin and melanoma | ||||||||||
| Melanoma | 8 | 6 | 4 | 6 | 3 | 1 | 2 | 0 | 2 | 1 |
| Non-melanoma | 2 | 2 | 2 | 2 | 0 | 1 | 1 | 0 | 0 | 0 |
| ASCT (general skin and melanoma) | 4 | 1 | 0 | 2 | 2 | 0 | 0 | 0 | 2 | 0 |
| Total | 14 | 9 | 6 | 10 | 5 | 2 | 3 | 0 | 4 | 1 |
| Grand total | 447 | 134 | 107 | 277 | 120 | 47 | 87 | 23 | 107 | 19 |
Each outpatient clinic with cancer types are listed, along with corresponding material counts and content counts. Totals for each clinic are listed, along with a final running total for all cancer types treated at the cancer center. A total of 447 PE material titles were found to be distributed across the 13 outpatient clinics. The average number of PE materials available ranged between 0 and 77 across outpatient clinics with an average of 34 PE materials per clinic
ASCT Applicable to Several Cancer Types